Kenvue INC

Kenvue Inc. shareholders elected all 12 director nominees, approved executive compensation, and ratified auditors at the 2026 Annual Meeting.

Kenvue Inc. announced first quarter 2026 financial results, showing a 4.5% increase in net sales and a significant 47% rise in diluted EPS.

Kenvue Inc. announces the appointment of Heather Howlett as interim Chief Financial Officer, effective May 12, 2026, following the departure of Amit Banati.

Kenvue Inc. announced that Chief Financial Officer Amit Banati will step down effective May 12, 2026, to become a CEO at another company, with an interim successor planned.

Kenvue Inc. stockholders overwhelmingly approved the merger agreement with Kimberly-Clark Corporation, moving closer to forming a global health and wellness leader.

Kenvue Inc. has filed an 8-K to supplement its merger proxy statement with Kimberly-Clark Corporation, addressing multiple shareholder litigations and providing updated financial analysis.

Kenvue Inc. reported increased net sales and operating income for the first quarter of 2026, driven by growth across its segments, while continuing preparations for its merger with Kimberly-Clark.

Kenvue reported a decline in Q3 2025 net sales and operating income, alongside announcing a definitive merger agreement with Kimberly-Clark Corporation.

Kenvue Inc. reported a significant increase in net income for the second quarter and first half of fiscal 2025, primarily driven by the absence of large impairment charges seen in the prior year, despite a decline in net sales across all segments.

Kenvue Inc. reports a decrease in net sales for Q1 2025, impacted by currency exchange rates and strategic price investments, while continuing its multi-year restructuring initiative.

Kenvue Inc. reported a slight decrease in net sales and a significant drop in net income for the third quarter of 2024, while also detailing ongoing restructuring initiatives.

Kenvue Inc. reported a mixed second quarter of 2024, with flat sales year-over-year, significant impairment charges, and the commencement of a multi-year restructuring initiative.

Kenvue Inc. reported a 2.1% decline in net sales for fiscal year 2025, alongside a 42.7% increase in net income driven by lower impairment charges, as it progresses towards a merger with Kimberly-Clark Corporation.

Kenvue Inc. details its financial performance for fiscal year 2024, highlighting its ongoing separation from J&J, restructuring initiatives, and strategic focus on consumer health.

Kenvue Inc.'s recent SEC filing outlines the company's common and preferred stock structure, voting rights, dividend policies, and measures designed to deter hostile takeovers.

Anindya Dasgupta, Group President APAC of Kenvue Inc., reported multiple transactions in common stock on July 31, 2026.

Kenvue Inc. director Jeffrey C. Smith reported changes in beneficial ownership of company stock, including the acquisition of deferred share units.

Richard E. Allison Jr., a Director at Kenvue Inc., reported the acquisition of 1,413 Deferred Share Units (DSUs) on June 29, 2026, as part of a deferred compensation plan.

Kenvue Inc. CFO and CAO Heather Howlett sold 3,700 shares of common stock at an average price of $18.105.

Kenvue Inc. Director Jeffrey C. Smith reported transactions involving common stock and deferred share units.

Kenvue Inc. reports that Director Sarah Hofstetter was granted 10,309 Deferred Share Units on May 21, 2026, under the company's director compensation plan.

Kenvue Inc. has filed its 2026 Proxy Statement, detailing the upcoming Annual Meeting of Shareholders where key proposals include the election of directors and the approval of the merger with Kimberly-Clark Corporation.

Kimberly-Clark Corporation and Kenvue Inc. announce a definitive merger agreement for K-C to acquire Kenvue in a cash and stock transaction valued at approximately $36.8 billion.

Kenvue's proxy statement supplement reveals details of related party transactions involving directors and companies providing market data analytics and consumer data services.

Kenvue Inc. has filed its definitive proxy statement with the SEC, signaling preparations for its upcoming annual meeting.

Kenvue's proxy statement highlights the company's progress in its first full year as an independent entity and outlines strategic priorities for future growth and shareholder value.

Kenvue Inc. will hold its Annual Meeting of Shareholders on May 23, 2024, to vote on the election of directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent accounting firm.

Kenvue Inc. files an S-1 registration statement for a secondary offering of 182,329,550 shares of common stock, as Johnson & Johnson plans to fully divest its remaining stake through a debt-for-equity exchange.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 7.0% of Kenvue Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has disclosed beneficial ownership of 143,924,768 shares, representing 7.5% of Kenvue Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership of Kenvue Inc. common stock following an internal realignment.

T. Rowe Price Associates, Inc. reported a 1.0% beneficial ownership stake in Kenvue Inc. common stock as of December 31, 2025.

T. Rowe Price Associates, Inc. reported an increased beneficial ownership of 6.0% in Kenvue Inc.'s common stock as of September 30, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 4.7% beneficial ownership in Kenvue Inc.'s common stock as of September 30, 2025.